Literature DB >> 3134063

Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin.

J B Bussel1, L C Pham, L Aledort, R Nachman.   

Abstract

Intravenous infusion of gammaglobulin (IVGG) has been extensively used in the treatment of immune thrombocytopenic purpura (ITP) in adults to acutely raise the platelet count but not as a maintenance therapy. This report describes the maintenance treatment of adults with chronic ITP using repeated infusions of 800 to 1,000 mg/kg of IVGG. Sixteen of 40 patients were able to discontinue all therapy after receiving between one and 15 infusions. Five patients achieved remission and 11 other patients became stable without therapy (SWT) maintaining a platelet count greater than 20,000/microL without bleeding. The average quantity of gammaglobulin received for all patients was 606 g per patient. Of the 30 patients who underwent but did not respond to splenectomy, 11 (37%) were able to discontinue all therapy by either achieving remission (5) or becoming SWT (6). None of the five patients who achieved remission did so after only the initial therapy; all first received between one and 12 maintenance infusions. The ten splenectomized patients who were unresponsive to IVGG also failed to subsequently respond to conventional therapy including immunosuppressive agents and androgens. No toxicity of IVGG was seen except for postinfusion headaches. IVGG is an effective although expensive maintenance therapy for adults with ITP and is useful in patients who have not responded to splenectomy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134063

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Current concepts in the treatment of immune thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 2.  Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Authors:  Roberto Stasi
Journal:  Blood Transfus       Date:  2010-11-26       Impact factor: 3.443

Review 3.  Immune thrombocytopenic purpura: current concepts.

Authors:  D J Tardio; J A McFarland; M F Gonzalez
Journal:  J Gen Intern Med       Date:  1993-03       Impact factor: 5.128

4.  IgG inhibits the increase of platelet-associated C3 stimulated by anti-platelet antibodies.

Authors:  S Nomura; Y Miyazaki; T Miyake; K Yamaguchi; H Kido; T Kawakatsu; T Fukuroi; H Kagawa; M Suzuki; M Yanabu
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

5.  Failure of repeated courses of high-dose intravenous immunoglobulin to induce stable remission in patients with chronic idiopathic thrombocytopenic purpura.

Authors:  C Schiavotto; M Ruggeri; F Rodeghiero
Journal:  Ann Hematol       Date:  1995-02       Impact factor: 3.673

Review 6.  Platelet therapy.

Authors:  V P Choudhry
Journal:  Indian J Pediatr       Date:  2002-09       Impact factor: 1.967

Review 7.  Intravenous immune globulin in recurrent abortion.

Authors:  O Heine; G Mueller-Eckhardt
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Prediction of the effect of immunoglobulin therapy in ITP.

Authors:  K Kawasugi; J Matsuda; T Abe
Journal:  Blut       Date:  1989-07

9.  Intravenous Immunoglobulin (IVIg) Utilization in Immune Thrombocytopenia (ITP): A Multi-Center, Retrospective Review.

Authors:  Cyrus C Hsia; Yang Liu; Kathleen Eckert; Neerav Monga; Julia Elia-Pacitti; Nancy M Heddle
Journal:  Drugs Real World Outcomes       Date:  2015-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.